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Background: Antiretroviral therapy (ART) markedly reduces HIV transmission, and testing and treatment programs
have been advocated as a method for decreasing transmission at the population level. Little is known, however,
about the extent to which sexually transmitted infections (STIs), which increase the HIV infectiousness of untreated
individuals, may decrease the effectiveness of treatment as prevention.
Methods: We searched major bibliographic databases to August 12th, 2014 and identified studies reporting differences
in HIV transmission rate or in viral load between individuals on ART who either were or were not co-infected with
another STI. We used hierarchical Bayesian models to estimate viral load differences between individuals with and
without STI co-infections.
Results: The search strategy retrieved 1630 unique citations of which 14 studies (reporting on 4607 HIV viral load
measurements from 2835 unique individuals) met the inclusion criteria. We did not find any suitable studies that
estimated transmission rates directly in both groups. Our meta-analysis of HIV viral load measurements among
treated individuals did not find a statistically significant effect of STI co-infection; viral loads were, on average,
0.11 log10 (95 % CI −0.62 to 0.83) higher among co-infected versus non-co-infected individuals.
Conclusions: Direct evidence about the effects of STI co-infection on transmission from individuals on ART is very
limited. Available data suggests that the average effect of STI co-infection on HIV viral load in individuals on ART
is less than 1 log10 difference, and thus unlikely to decrease the effectiveness of treatment as prevention. However,
there is not enough data to rule out the possibility that particular STIs pose a larger threat.Background
A large body of evidence suggests that antiretroviral therapy
(ART), particularly with newer treatment regimens, mark-
edly reduces the risk of sexual transmission of HIV. Recent
systematic reviews have estimated that ART causes a more
than ten-fold reduction in the incidence rate within discord-
ant couples, to less than 0.5 per 100 person-years [1–6].
These sharp reductions have inspired the idea of anti-
retroviral treatment as prevention—aggressive programs
to identify and treat HIV-positive individuals could* Correspondence: david.champredon@gmail.com
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by reducing the infectiousness of HIV-infected individuals
[5, 7]. However, increased infectiousness when treated indi-
viduals are co-infected with one or more other sexually
transmitted infections (STIs) could potentially undercut the
effectiveness of treatment as prevention programs. Concern
with the effects of co-infection on HIV transmission is ex-
emplified in the 2008 “Swiss Statement,” which argues that
HIV sexual transmission risk is of no concern within stable
discordant relationships in which: an HIV-positive partner
is adhering to treatment under the care of a physician; the
viral load has been suppressed for at least six months; and
no other STIs are infecting the HIV-positive partner [8].cess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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increased risk are not fully understood, many STIs have
been associated with higher risks of both HIV acquisition
and sexual transmission [9–15]. Increased HIV transmis-
sion may be underpinned by higher HIV viral load
resulting from larger concentration of HIV-infected im-
mune cells in genital secretions induced by an inflamma-
tory response and/or additional pathways caused by genital
ulcers [16]. Similarly, inflammatory STIs, by recruiting
immune cells, may provide additional targets for HIV
virions, increasing HIV acquisition risk. Ulcerative STIs
may present additional entry points for HIV infection [15].
Studies of HIV-STI interactions have been conducted
mostly on individuals not receiving ART. Less is known
about the impact of STI co-infections on HIV shedding
from treated individuals. STI prevalence is high among
HIV-infected individuals [17] and the proportion of these
individuals on ART is quickly rising [18]. Thus, any poten-
tial increased HIV infectiousness due to STI co-infections
among treated individuals could have important epidemio-
logical consequences as treatment as prevention becomes
more widespread.
Disentangling the many interacting factors at play is
challenging: many STIs are suspected of affecting HIV
shedding [9] and it remains unclear whether how these
effects interact in people with more than one such in-
fection; the viral load response to ART is regimen- and
gender-specific [19]; numerous (not necessarily consist-
ent) methods are used to sample and quantify HIV viral
load [20, 21]; viral load measurements can vary between
anatomical sites within an infected individual [22]; and
HIV viral loads exhibit substantial temporal variation [23].
When considering transmission events in discordant cou-
ples, isolating the effect of STI co-infections is challenging
because concomitance of STI infections in both partners
(that could affect both HIV susceptibility and infectiousness)
and HIV transmission are often not practical to ascertain.
Here, we conduct a systematic review and meta-analysis
of the available evidence to assess whether STI co-
infections affect the risk of HIV transmission from indi-
viduals on ART. We searched for studies that estimated
transmission directly, and also for studies that measured
viral load, which we intended to use as a proxy for trans-
mission if the direct evidence was insufficient.
Methods
This systematic review and meta-analysis followed the
guidelines from the PRISMA statement [24] (see Additional
file 1). A protocol was prospectively registered in the
PROSPERO database (see Additional file 2). Published
peer-reviewed observational studies and randomized con-
trolled trials were considered for inclusion. We included
studies of sexually active HIV-infected participants on ART
that were further classified into two subgroups: participantswhose only known STI was HIV (the “mono-infected
group”) and those with HIV and co-infected with another
STI (the “co-infected group”). Studies were eligible for
inclusion if they measured HIV viral loads among
HIV-infected participants, or if they observed at least
monthly HIV transmission events and STI infection
status in discordant couples. An individual was consid-
ered co-infected only if the STI was laboratory con-
firmed. Individuals with ongoing treatment for the co-
infecting STI were not included.
We searched for all relevant studies in Medline (Ovid),
EMBASE (Ovid), PubMed, CINAHL and the Cochrane
Library from inception to August 12th, 2014. Subject
headings and text words associated with the risk of HIV
sexual transmission, ART and STIs were included in the
search strategies. We included STIs commonly discussed
in the context of HIV transmission: Chlamydia trachoma-
tis, chancroid (H. ducreyi), any type of Human Papilloma
Virus, Herpes Simplex Virus 2, Neisseria gonorrhoeae,
syphilis (T. pallidum) and Trichomoniasis (T. vaginalis).
We also included bacterial vaginosis and candidal vagin-
itis, although these are not known to result directly from
sexual transmission, and urethritis, which can be associ-
ated with more than one STI. The search did not impose
any language or geographical restrictions on studies. The
STI positivity definitions are given in Additional file 3 and
full search strategiesin Additional file 4.
All retrieved abstracts were read by three authors (DC,
CS and SH). Eligibility assessment was performed independ-
ently by two authors for each abstract, using pre-defined
guidelines. Disagreement between authors was resolved by
consensus after discussion. Data from eligible studies were
extracted independently by two authors (DC and SH).
We sought to assess how two primary outcomes of inter-
est, HIV viral loads and HIV transmission rates within dis-
cordant couples, varied between HIV-infected participants
on ART with and without STI co-infections. We sought
additional data to assess potential sources of bias within
and between studies including STI diagnostic methods;
anatomical sites sampled for HIV viral load measurements;
HIV assays; interval between STI co-infection diagnosis
and HIV viral load measurement; ART regimen, treatment
length and adherence; study design; HIV-infected partici-
pant age, gender, and sexual orientation; and, for serodis-
cordant couple studies, concomitance of STI co-infection
in HIV-uninfected partner and HIV genetic linkage follow-
ing secondary partner seroconversion. Within studies, we
excluded individuals not explicitly known to be on ARTand,
when this information was available, those who had been on
ART for less than 30 days. We probed study quality by
summarizing variables and methods (Tables 1 and 2),
and with forest and funnel plots (Figs. 3 and 4).
Planned measures of effect were: the difference in log10
HIV viral load between the mono- and co-infected groups,
Table 1 Summary table of studies included in the meta-analysis
Study Study objective Country Population Coverage
period
Study design STI STI assessment
method
Number of
participants
Individuals
included in
meta-analysis
HIV viral load
measure
HIV VL
anatimical
site
Adolf 2012 [31] Prevalence and risk
factors for syphilis
among HIV+
Brazil Females and
males; STI/HIV
clinic patients-
SoBrHIV cohort
1991–2008 Case-control Tp VDRL, FTA 1012 759 Not reported Blood
plasma
Anderson 2008 [32] Association between
presence of
inflammatory
USA Females; STI/HIV
clinic patients
Not
reported
Prospective
cohort
Bv Ct Cv
Ng Tp Tv
Bv: Amsel 97 41 RNA Blood and
CVL
Ct, Ng: culture
Cv: visual
exam
Tv: wet mount
Tp: RPR
Conley 2010 [33] Prevalence and risk
factors for abnormal
anal cytology among
HIV+
USA Females and
males; STI/HIV
clinic patients -
SUN study
2004–2006 Prospective
cohort
Ct HPV
HSV Ng
Tp Tv
HPV, Ng, Ct:
NAAT, cytological
621 147 RNA Not
reported
Tv: NAAT
HSV2: serology
Chan 2008 [12] Correlation between
HIV VL in blood and
semen among men
both ART naive and
experienced
Australia Males; STI/HIV
clinic patients
2003–2006 Prospective
cohort
Ct Ng Tp Ct: NAAT 119 81 RNA Blood and
semen
Ng: culture
Tp: Fabs + RPR
Cu-Uvin 2001 [26] Impact of genital tract
infections on HIV
cervicovaginal shedding
USA Females; STI/HIV
clinic patients
Not
reported
Prospective
cohort
Bv Cv Tv Bv: Amsel 108 61 RNA Blood and
CVL
Cv, Tv: culture
Graham 2011 [34] Impact of genital
ulcerations on HIV
genital shedding
Kenya Females; STI/HIV
clinic patients
2004–2008 Prospective
cohort nested
Bv Ct Cv
Hd Ng Tp
Tv
Tv: wet mount 145 37 RNA Cervix and
vagina
Bv: Nugent
Cv: not reported
Ng: culture +
NAAT
Ct: NAAT
Hd: culture
Tp: serology
Jarzebowski 2012
[35]
Impact of syphilis on
CD4 and HIV VL
France Males; MSM-
FHDH cohort
1998–2006 Case-control Tp Not reported 1515 1271 RNA Blood
plasma
Kofoed 2006 [36] Impact of Syphilis
infection on CD4,
HIV VL and response
after anti-treponemal
treatment
Denmark Males; MSM 2003–2004 Prospective
experimental
Tp Dark field,
serology
38 34 RNA Blood
plasma
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Table 1 Summary table of studies included in the meta-analysis (Continued)
Madeddu 2014 [41] HPV screening should
be done even on
HIV-positive women
on ART
Italy Females; STI/HIV
clinic patients
2008–2009 Prospective
cohort
HPV NAAT 57 52 RNA Blood
plasma
Politch 2012 [37] Prevalence of seminal
HIV shedding among
MSM on ART
USA Males; MSM Not
reported
Prospective
cohort
Ct HSV Ng
Tp NGU
HSV: serology 101 96 DNA and
RNA free and
RNA assoc
Semen
Ct, Ng, Tp: not
reported
Sadiq 2002 [38] Effect of urethritis on
seminal HIV VL for
patients on ART
UK Males; MSM 1998–2000 Prospective
cohort
Ct Ng
NGU
Ng: culture 40 39 RNA and
DNA
Blood and
semen
Ct: NAAT
Sha 2005 [39] Association of Bv and
Bv-associated bacteria
with HIV genital VL
USA Females; STI/HIV
clinic patients
1994–1997 Prospective
cohort
Bv Ct Cv
HPV HSV
Ng Tp Tv
Bv: Amsel +
Nugent
362 107 RNA Blood and
CVL
Tp: symptoms +
DFA
Ct, Ng: culture +
pap
HSV: symptoms +
pap
HPV: NAAT
Sudenga 2012 [40] HSV2 epidemiology
in HIV+/at risk adolescents
USA Females and
males; adolescent;
REACH cohort
1996–2000 Case-control Bv Ct Hd
HPV HSV
Ng Tp Tv
HSV2: serology 513 60 RNA Blood
plasma
Ct, Ng, HPV:
NAAT
Bv: gram stain +
clinical criteria
Tv: culture
Winter 1999 [10] Impact of asymptomatic
urtethritis on HIV VL
in semen
UK Males; STI/HIV
clinic patients
Not
reported
Prospective
cohort
Ct Ng
NGU
Ng: Gram stain,
culture
94 53 RNA cell free Blood and
semen
Ct: NAAT
MSM: men who have sex with men
Bv Bacterial vaginosis, Cv Candidal vaginitis, Ct Chlamydia trachomatis, HPV, human papillomavirus, HSV human simplex virus type 2, Ng Neisseria gonorrhoeae, Tp Treponema pallidum, Tv Trichomonas vaginalis,
Ur urethritis
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Table 2 Assessment of risk of bias within studies
Study Number of
STIs tested
Sampling site
for HIV
Art adherence
reported
Adolf 2012 1 Blood plasma No
Anderson 2008 6 Blood and CVL No
Conley 2010 6 Not reported No
Chan 2008 3 Blood and semen No
Cu-Uvin 2001 3 Blood and CVL No
Graham 2011 7 Cervix and vagina Yes
Jarzebowski 2012 1 Blood plasma No
Kofoed 2006 1 Blood plasma No
Madeddu 2014 1 Blood plasma Yes
Politch 2012 4 Semen No
Sadiq 2002 2 Blood and semen No
Sha 2005 8 Blood and CVL No
Sudenga 2012 8 Blood plasma Yes
Winter 1999 2 Blood and semen No
Studies reporting a large number of STIs tested
ART adherence and measuring HIV, VL viral load in genital secretions are less
likely to bias estimates of the effect of STI co-infection on HIV transmission,
CVL cervicovaginal lavage
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transmission rate between HIV-discordant couples with
the infected partner belonging to the mono- versus co-
infected group.Statistical analysis
This review aims to gather all available evidence regard-
ing the effect of STI on HIV infectiousness, whether this
was the primary objective of a study or not. Hence,Table 3 Number of HIV viral loads measurements included in
the meta-analysis by STI co-infection and anatomical sites
STI Blood Cervicovaginal Semen Total
Bv 51 52 n/a 103
Ct 9 0 9 18
Cv 2 9 n/a 11
HPV 260 76 0 336
HSV 86 0 60 146
Ng 9 2 9 20
Tp 656 2 2 660
Tv 4 4 0 8
Ur 9 n/a 12 21
none 2915 192 177 3284
Total 4001 337 269 4607
Category “none” means there was no STI (other than HIV) co-infecting the patient
Bv bacterial vaginosis, Cv candidal vaginitis, Ct Chlamydia trachomatis, HPV
human papillomavirus, HSV human simplex virus type 2, Ng Neisseria
gonorrhoeae, Tp Treponema pallidum, Tv Trichomonas vaginalis, Ur urethritis, n/
a not applicableheterogeneity in study design is inevitable. For example,
HIV viral load can be measured at different anatomical
sites, with different sampling techniques, for patients with
different STI co-infections. Estimating a single sum-
mary statistic for such heterogeneous effects is challen-
ging. Adopting a classical approach to conduct the meta-
analysis would make it difficult to fit all the studies into
one modelling framework. For example it might be ne-
cessary to choose a threshold and dichotomize data
from studies providing continuous HIV viral load in
order to compare them with the ones providing dichot-
omous data only. Hierarchical Bayesian models offer a
flexible framework to coherently incorporate heteroge-
neous variables that theoretically relate to a common ef-
fect while providing estimates of the variability at each
conceptual level [25].
We therefore used a Bayesian hierarchical model to
estimate—across heterogeneous studies—an overall effect
of STI co-infection on HIV viral load, while also estimat-
ing how this effect differed depending on the anatomical
site sampled for viral load measurements and on the spe-
cific STI co-infection. Similarly, we also estimated how
the effect of STI co-infection differed between studies and
included individual-level random effects for longitudinal
studies. Studies where the only outcome available was di-
chotomous (HIV viral load above or below a stated thresh-
old) [10, 12, 26] were combined with studies that provided
continuous outcomes by introducing latent variables [27].
We used uninformative priors for all effect sizes and their
variances [28]. The details of the model and our prior
choices are provided in Additional file 5. The model was
developed in R version 3.0.2 [29] with package RSTAN
version 2.2.0 [30]. Code is available upon request.
Results
Systematic review
Our database searches identified 2997 citations. In addition,
23 records were identified outside the database search
(mostly via references cited in the publications retrieved
from the database search). After duplicates were removed,
1630 records were assessed for eligibility (Fig. 1). We ex-
cluded 1277 records with abstracts that obviously did not
meet our inclusion criteria, leaving 353 to be assessed with
a full-text review. When studies appeared to have obtained
but not published data relevant to our meta-analysis, we
requested them from the original investigators. Of 73 in-
vestigators contacted for additional data, 21 responded
and 10 provided data. This second screening identified 14
studies with sufficient information to be included in the
meta-analysis [10, 12, 26, 31–41]. All studies included in
our meta-analysis were approved by an ethics committee.
Table 1 summarizes the main characteristics of each
eligible study. No studies involving discordant couples
Fig. 1 Flow chart of the selection process
F3
F4
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dence and STI status at least monthly (our threshold to
ascertain concomitance). Hence our findings are limited
to an indirect measurement of HIV-infectiousness as mea-
sured by viral load at various anatomical sites. Of these 14
studies, two studies included participants from resource-
limited countries [31, 34]; four studies focused on MSM
[35–38]; and two reported on ART adherence [34, 40].
Syphilis, chlamydia and gonorrhea were the most reported
STIs in the eligible studies. We provide further detail on
the STI co-infections tested for and the anatomical sites
sampled by each study in the Additional file 6.
Three studies included in this review [31, 33, 40] did
not focus on differences in HIV infectiousness between
STI co-infected and HIV mono-infected groups as a pri-
mary outcome. Among the 11 other studies, 7 suggest that
co-infection with another genital infection may be associ-
ated with an increase in HIV viral load [10, 26, 35–39].
Table 2 outlines the main features from studies that
could bias our estimates. The more STIs tested, the smaller
the risk of incorrectly categorizing individuals as mono-
infected. Six studies [32–34, 37, 39, 40] out of 14 reported
on testing more than 4 STIs (in addition to HIV). Report-
ing adherence to ART reduces statistical misattribution of
the reasons for increases in HIV viral load. Three studies
[20, 34, 41] out of 14 explicitly reported adherence to ART.
Because of HIV compartmentalization [42] (viral con-
centration may substantially differ between different ana-
tomical sites within the same individual at a given time),
measuring HIV viral load in genital or anal secretions ismost relevant when considering sexual transmission. Eight
out of 14 studies measured HIV viral load in such anatom-
ical sites [10, 12, 26, 32, 34, 37–39].Meta-analysis
The 14 studies included in the meta-analysis represent
4607 visits from 2835 unique individuals (Table 3). The
posterior distributions of effect sizes for each study, aver-
aged across the associated STIs and anatomical sites, are
shown in Fig. 2. We estimated that, among HIV-infected
individuals on ART, the presence of another STI co-
infection was associated with an HIV viral load 0.11 log10
(95 % CI −0.62 to 0.83) higher than in HIV mono-infected
individuals, averaging over both anatomical sites and dif-
ferent STIs. Thus, we did not find a statistically significant
effect of STI co-infection on the viral load of HIV-infected
individuals on ART. Similarly, we did not find any statisti-
cally significant effect of STI co-infections on viral load
when examining the effect on viral load as measured at a
particular anatomical site, or for a particular STI co-
infection, although we note that most of the posterior dis-
tributions for the effects of co-infection on viral load had
positive means (Fig. 3).
Figure 4 shows a funnel plot of included studies and
doesn’t exhibit a strong asymmetry, hence suggests no ob-
vious publication bias. Another risk of bias across studies
could have been introduced if temporal changes in STI
prevalence and ART regimens were not adequately cap-
tured by the model.
Forest plot of the average effect−size for each studies
(any STI, any anatomical site)
Difference HIV log10 Viral Load
215.005.0−1−
Adolf 2012
Anderson 2008
Chan 2008
Conley 2010
Cu−Uvin 2001
Graham 2011
Jarzebowski 2012
Kofoed 2006
Madeddu 2014
Politch 2012
Sadiq 2002
Sha 2005
Sudenga 2012
Winter 1999
Pooled Estimate
HIV VL lower
when STI co−infection
HIV VL higher
when STI co−infection
Fig. 2 Posterior means and 95 % credible intervals of the effect size for each study included in the meta-analysis. The effect size is expressed as
the difference of HIV viral load (log10) between an individual HIV positive, co-infected with any other STI and an individual only infected with HIV.
The black square represents the posterior mean, with its area proportional to study sample size. The red diamond and arrows reflect estimates of
the pooled effect (i.e., across all studies, STIs and anatomical sites)
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summary effect size (using the I2 statistic [43]) could not
be reliably captured because of the large variance associ-
ated with our estimates (see Additional file 5). Three stud-
ies [31, 39, 40] exhibited HIV viral loads indicative of
incomplete viral suppression in a non-negligible proportion
of participants (i.e. HIV viral load above 4 log10). We did a
sensitivity excluding these studies and did not find any
qualitative differences in our results (see Additional file 7).
Visits where patients were co-infected with two or more
STIs other than HIV (381 out of 4219 total visits) were
not used in the main analysis because our model structure
specified unique effects for each type of STI co-infection;
we used a sensitivity analysis to explore the effects of this
exclusion and found no qualitative impact on our results
(see Additional file 7).Discussion
In the absence of qualifying studies that measured trans-
mission risk directly, we conducted a meta-analysis of
all available evidence of increased HIV viral load due to
STI co-infection of individuals on ART, as a proxy for
increased infection risk. Pooling information from all
available studies, anatomical sites, and co-infections, we
estimated that the average difference in viral load due
to STI co-infection of individuals on ART was 0.11 log10
(95 % CI −0.62 to 0.83) greater than HIV mono-infected
individuals.
Although our study provides some evidence for a small
effect of STI co-infection on viral loads, we cannot rule
out the possibility of no effect, or the possibility of a mod-
erately large effect (the upper credible interval is 0.83
log10). Importantly, we are also not able to rule out the
Forest plot of the average effect−size 
by STI and anatomical site
Difference HIV log10 Viral Load
215.005.0−1−
Bv_Blood
Bv_Cervicovaginal
Ct_Blood
Ct_Semen
Cv_Blood
Cv_Cervicovaginal
HPV_Blood
HPV_Cervicovaginal
HSV_Blood
HSV_Semen
Ng_Blood
Ng_Cervicovaginal
Ng_Semen
Tp_Blood
Tp_Cervicovaginal
Tp_Semen
Tv_Blood
Tv_Cervicovaginal
Ur_Blood
Ur_Semen
Pooled Estimate
HIV VL lower
when STI co−infection
HIV VL higher
when STI co−infection
Fig. 3 Forest plot for a given STI/anatomical site pair. Posterior means and 95 % credible intervals of the effect size for each study included in the
meta-analysis. The effect size is expressed as the difference of HIV viral load (log10) between an individual HIV positive, co-infected with an STI
and an individual only infected with HIV. The black square represents the mean of the distribution, its area is proportional to the number of data
points associated with the specific STI/anatomical site pair; segments represent the 95 % credible intervals (CI). The red diamond shows the mean
of the pooled effect (across all studies, STIs and anatomical sites) and the segment its 95 % CI. Bv: Bacterial vaginosis; Ct: Chlamydia trachomatis;
Cv: Candidal vaginitis; Bacterial vaginosis; HPV: human papillomavirus; HSV: human simplex virus type 2; Ng: Neisseria gonorrhoeae; Tp: Treponema
pallidum; Tv: Trichomonas vaginalis; Ur: urethritis
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STIs and anatomical site) have a much larger effect (see
Fig. 3). Nonetheless, based on our analysis, we cautiously
posit that ART manages—on average—to sustain its ef-
fectiveness at keeping HIV viral loads low during STI co-
infection episodes, at the anatomical sites considered in
this review (blood plasma, semen and cervicovaginal), and
thus would be expected to maintain its effectiveness at
preventing transmission.
Even with nearly 5000 data points used in this meta-
analysis, realistic consideration of the variation between
studies, STIs and anatomical sites reduces the statistical
power considerably. There are other limitations that need
to be highlighted.
Because eligible studies only estimated HIV viral loads,
not transmission rates in discordant couples, our summaryeffect size is a proxy for HIV infectiousness and might not
be an accurate representation of the actual sexual trans-
mission risk. There were no eligible studies measuring
rectal HIV viral load, so our estimate may not be ap-
plicable in assessing change in HIV infectiousness from
receptive anal intercourse.
Not all studies tested for all STIs, hence we may have
misclassified some co-infected individuals. This misclassi-
fication is likely, given the high prevalence rate of other
STIs in the HIV-infected population [17]. Such misclassifi-
cation could bias our estimates of the effect of STI on
HIV viral load downwards.
Our study focused on whether STIs could interfere
with viral suppression, and we therefore excluded HIV
VL measurement done within 30 days of ART initiation.
It seems likely that the effects of STIs on HIV viral load
0.15.00.05.0−0.1−
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Fig. 4 Funnel plot. The horizontal axis represents the mean posterior effect size for each study (the log10 HIV viral load between HIV positive
individuals with and without STI co-infection), the vertical axis is the effect size precision (inverse of the standard deviation) of the associated
study. Each point represents a study. The solid vertical line represents the mean effect size and the solid curved lines represent its 95 % CI. The
dashed vertical line represents a null effect size (no HIV viral load difference)
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treatment begins and decline gradually through time, in
an STI-specific fashion. We did not find any studies that
could provide evidence bearing directly on the effect of
STIs when ART has been initiated recently.
Adherence to ART was rarely reported or measured in
the studies we used. Since the effect of STI co-infection
on viral load would be stronger in people with poorly
controlled viral loads, this effect is likely to bias our re-
sult. This bias will be exacerbated if co-infected individ-
uals exhibit lower adherence (or could be reduced, or
even reversed, if they are more likely to adhere, perhaps
due to symptoms from the other STIs).
Most HIV viral load observations included in this meta-
analysis were measured in blood plasma, not in genital se-
cretions, which may limit the interpretation of our effect
size to actual sexual transmission risk. Indeed, while plasma
and genital HIV viral loads are correlated [44], evidences of
HIV compartmentalization in some treated patients where
viral loads as measured in genital secretions remain com-
patible with a non-negligible risk of transmission despite
very low blood plasma viral loads [37, 45, 46].We did not estimate gender-specific effects to avoid
further complicating our model. It is possible that gender
confounds our results to some extent. We note, however,
that such confounding would be limited to blood mea-
surements, since gender is implicitly accounted for in the
other anatomical sites studied. Also, our estimate did not
include a potential effect of menstrual cycle on genital
HIV viral load, but we note that a recent study did not ob-
serve such effect [47].
If STIs were indeed an escape route for treatment as
prevention, one could argue this should have shown up
during large trials studying transmission rate among
HIV discordant couples (for example [5]). But such trials
do not provide complete reassurance, since trial partici-
pants are given STI monitoring and treatment not avail-
able to the general population.
The number of HIV-infected individuals receiving ART
has dramatically increased during the last 10 years—from
less than half a million in 2003 to about 13 million in
2013—and will increase further [18, 48]. The extended life
expectancy associated with ART and the potentially higher
exposure to STIs of the HIV-infected population may
Champredon et al. BMC Infectious Diseases  (2015) 15:249 Page 10 of 11increase the prevalence of STI co-infections, particularly
with public awareness of the decreased infectiousness of
HIV while on ART and a potentially consequential de-
crease in condom usage. Hence, understanding the effects
of such co-infections on HIV sexual transmission is an im-
portant public health issue.
Our study provides some insights into whether STI
co-infections can undercut treatment as prevention ef-
forts. Pooling available data, we estimate the degree to
which STI co-infection may increase or decrease HIV
shedding among treated individuals. We found a 95 %
upper bound corresponding to a 0.83 log10 increase,
which suggests that elevation of viral load by STI co-
infections is unlikely to have a major impact on the abil-
ity of ART to reduce of HIV sexual transmission from
patients on effective ART (as opposed to what could be
observed in populations not on ART).
It is important to note that our results do not under-
cut the importance of control and treatment of STIs, not
only for the well-being of infected individuals, but also
for reducing HIV sexual transmission at the whole popu-
lation level, which still has a majority of HIV infected in-
dividuals not on effective ART [18].
We did not have sufficient data to single out the effect
of a specific STI on HIV viral load at a given anatomical
site. Given the heterogeneous effect of STIs on HIV in-
fectiousness, our analysis may have failed to identify epi-
demiologically relevant effects of particular STIs.
Hence, an important finding of our systematic review
is that there is a paucity of available data with a sufficient
level of detail to ascertain the effects of STI co-infection
on the risk of HIV sexual transmission risk for individuals
on ART. Future studies considering either transmission
rate or HIV viral load may wish to consider the following
suggestions: (i) given the possible high prevalence of
co-infections among HIV-infected individuals, a broadest
spectrum of relevant STIs should be tested; for transmis-
sion studies, testing should be performed frequently in
both partners; (ii) HIV viral load should be measured in
genital/rectal secretions, not blood plasma only; (iii) ART
regimens and adherence should be reported, ideally at the
patient level. We recognize that these suggestions may not
always be practical, but when they can be followed they
will help clarify the potentially important effects of STI-
coinfection on the risk of HIV sexual transmission.
Conclusions
Our findings suggest that, on average, ART maintains its ef-
fectiveness at controlling HIV viral load during STI co-in-
fections. However, with currently available data, we cannot
rule out the possibility that certain STI co-infections have a
larger effect. More high-quality studies specifically aimed at
investigating the impact of STIco-infection on HIV sexual
transmission from individuals on ARTare needed.Additional files
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